Table 3.
distribution of the stage of development, the decrease of TGR and the tumor response (RECIST) across the different trials
| Investigational regimen | Decrease of TGR* | RECIST Evaluation | Total number of patients (N) | Current development status | ||
|---|---|---|---|---|---|---|
| Progressive Disease (N) | Stable Disease (N) | Partial Response (N) | ||||
| Trial # 1: HSP inhib. | Not Significant | 3 | 5 | 0 | 8 | Stopped |
| Trial # 2: HSP inhib. | Not Significant | 10 | 11 | 0 | 21 | Ongoing |
| Trial # 3: Cell-Cycle inhib. | Not Significant | 3 | 9 | 0 | 12 | Stopped |
| Trial # 4: PI3K/Akt/mTOR inhib. | Not Significant | 2 | 7 | 0 | 9 | Ongoing |
| Trial # 5: Antiangiogenic | Not Significant | 3 | 4 | 1 | 8 | Ongoing |
| Trial # 6: HDAC inhib. | Not Significant | 9 | 11 | 0 | 20 | Ongoing |
| Trial # 7: PI3K/Akt/mTOR inhib. | Significant | 3 | 7 | 2 | 12 | Ongoing |
| Trial # 8: MEK inhib. | Significant | 3 | 8 | 2 | 13 | Stopped |
| Trial # 9: Antiangiogenic | Significant | 3 | 9 | 2 | 14 | Ongoing |
| Trial # 10: HER family inhibitor | Significant | 6 | 11 | 0 | 17 | Stopped |
| Trial # 11: Antiangiogenic | Significant | 3 | 15 | 2 | 20 | Ongoing |
| Trial # 12: PI3K/Akt/mTOR inhib. | Significant | 2 | 14 | 3 | 19 | Ongoing |
*
Significance of the decrease of TGR between the REFRENCE and the EXPERIMENTAL period (pairwise comparison, wilcoxon signed-rank test).